EU-US plans for joint funding of rare diseases research unveiled to industry

18.07.2011
Science Business

A new transatlantic alliance showcased its ambition to develop diagnostics for 8,000 rare diseases and double the number of registered Orphan drugs for rare conditions by 2020, at the Biotechnology Industry Organization (BIO) meeting in Washington. The European Commission and the US National Institutes of Health (NIH) is putting together a jointly-funded programme of research to capitalise on advances in genomics and speed up the development of diagnostics and treatments for rare diseases. 

Read more on Science Business.